Breast Cancer Grand Round with Dr Michelle Li
Antibody-drug conjugates (ADCs) in cancer treatment
June 11 2025
Antibody-drug conjugates (ADCs) have rapidly emerged as a highly effective strategy in the treatment of cancers of different histologies, including metastatic breast cancer. The use of engineered monoclonal antibodies that target a tumour-associated antigen and are linked to a cytotoxic payload offers the opportunity for more precise delivery of chemotherapy.
With the use of trastuzumab deruxtecan, sacituzumab govitecan and other ADCs becoming increasingly more common in our clinical practice, several gaps in our knowledge are raised – including the mechanisms behind development of cross-resistance, and the most optimal sequencing of treatments to provide maximal benefit to our patients.
Warning: The VCCC Alliance Breast Cancer Grand Round is targeted at a clinical audience and features open discussion about real cases and patients. While these cases are de-identified, the imagery, content and discussion can be graphic. It is not appropriate for consumer participants.
Speaker
Dr Michelle Li
Medical Oncologist, Peter MacCallum Cancer Centre; PhD Candidate, The University of Melbourne
Dr Michelle Li is a medical oncologist with a strong interest in breast cancer, clinical trials and access to equitable healthcare. She is a recipient of the 2025 Breast Cancer Trials Clinical Fellowship, which will fund her research into identifying mechanisms and biomarkers of resistance to antibody-drug conjugates in the treatment of metastatic breast cancer.
Resource details
This course is brought to you by
